Following a plea from the president of Wuhan Jinyintan Hospital for recovered patients to donate plasma to save lives, on the evening of February 13, the State-owned Assets Supervision and Administration Commission of the State Council News Center announced on its official microblog that China Biotechnology Corporation has completed the collection of plasma from some of the recovered patients to carry out the preparation of new coronavirus special immune plasma products and special immune globulin. “After rigorous blood biosafety testing, virus inactivation, and antiviral activity testing, etc., the special-free plasma for clinical treatment has been successfully prepared.” China Bio’s official microblogging site also released a news release saying that the current clinical treatment of 10 critically ill patients through plasma collection from recovered patients with New Coronavirus pneumonia showed that the patients’ clinical signs and symptoms improved significantly after 12 to 24 hours of treatment, indicating that the special immune plasma products are effective in treating New Coronavirus infection. At the same time, both the SASAC News Center and the official microblog of China Bio released an initiative letter imploring recovered patients to actively donate blood. At around 00:00 on February 14, Nando’s reporter learned from China Bio’s staff that from 14 onwards, the blood donation house at the Hubei Provincial People’s Hospital in Wuhan will officially accept plasma donations from people recovering from New Coronavirus pneumonia. According to China Biologics news, since January 20, China Biologics has implemented the plasma collection for New Coronary Pneumonia survivors in Wuhan area. on February 8, the first phase of New Coronary Special Exemption plasma treatment for 3 critically ill patients was carried out in the First People’s Hospital of Jiangxia District, and now together with the follow-up hospital treatment for more than 10 critically ill patients. Clinically, the patients reflected that after 12 to 24 hours of treatment, the main inflammatory indicators in laboratory tests decreased significantly, the proportion of lymphocytes increased, key indicators such as blood oxygen saturation and viral load improved across the board, and clinical signs and symptoms improved significantly. According to China Biologics, experts believe that in the absence of a vaccine and specific therapeutic drugs, the use of this special immune plasma product is the most effective way to treat neocoronavirus infection and can significantly reduce the death rate of critically ill patients. According to “sky-eye search”, the full name of China Biotechnology Company Limited, founded in 1989, the registered capital of 7.5 billion yuan, the legal representative Yang Xiaoming, the company belongs to the China National Pharmaceutical Group Corporation. On the evening of February 13, at the 23rd press conference on the prevention and control of the epidemic in Hubei Province, Zhang Dingyu, president of Wuhan Jinyintan Hospital, appealed and implored recovered people to donate blood plasma. Zhang Dingyu said, “Because recovered patients have a large amount of comprehensive antibodies in their bodies to fight the virus, we also call on some recovered patients to actively come to the hospital, extend your arms and donate valuable plasma to work together to save the patients who are still fighting the virus.” The central steering group medical rescue team experts, Beijing Chaoyang Hospital Vice President Tong Zhaohui also said that the recovery period plasma treatment will be further observed in the future, and currently also see some good signs. Content source: Southern Metropolis Daily